These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 30922100)

  • 1. Irritability and Its Clinical Utility in Major Depressive Disorder: Prediction of Individual-Level Acute-Phase Outcomes Using Early Changes in Irritability and Depression Severity.
    Jha MK; Minhajuddin A; South C; Rush AJ; Trivedi MH
    Am J Psychiatry; 2019 May; 176(5):358-366. PubMed ID: 30922100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of Acute-Phase Treatment Outcomes by Adding a Single-Item Measure of Activity Impairment to Symptom Measurement: Development and Validation of an Interactive Calculator from the STAR*D and CO-MED Trials.
    Jha MK; South C; Trivedi J; Minhajuddin A; Rush AJ; Trivedi MH
    Int J Neuropsychopharmacol; 2019 May; 22(5):339-348. PubMed ID: 30958879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reevaluating the Efficacy and Predictability of Antidepressant Treatments: A Symptom Clustering Approach.
    Chekroud AM; Gueorguieva R; Krumholz HM; Trivedi MH; Krystal JH; McCarthy G
    JAMA Psychiatry; 2017 Apr; 74(4):370-378. PubMed ID: 28241180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of a Machine Learning Model Based on Pretreatment Symptoms and Electroencephalographic Features to Predict Outcomes of Antidepressant Treatment in Adults With Depression: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
    Rajpurkar P; Yang J; Dass N; Vale V; Keller AS; Irvin J; Taylor Z; Basu S; Ng A; Williams LM
    JAMA Netw Open; 2020 Jun; 3(6):e206653. PubMed ID: 32568399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline depression severity as a predictor of single and combination antidepressant treatment outcome: results from the CO-MED trial.
    Friedman ES; Davis LL; Zisook S; Wisniewski SR; Trivedi MH; Fava M; Rush AJ;
    Eur Neuropsychopharmacol; 2012 Mar; 22(3):183-99. PubMed ID: 21920711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of antidepressant medication treatment on suicidal ideation and behavior in a randomized trial: an exploratory report from the Combining Medications to Enhance Depression Outcomes Study.
    Zisook S; Lesser IM; Lebowitz B; Rush AJ; Kallenberg G; Wisniewski SR; Nierenberg AA; Fava M; Luther JF; Morris DW; Trivedi MH
    J Clin Psychiatry; 2011 Oct; 72(10):1322-32. PubMed ID: 22075098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations.
    Sung SC; Haley CL; Wisniewski SR; Fava M; Nierenberg AA; Warden D; Morris DW; Kurian BT; Trivedi MH; Rush AJ;
    J Clin Psychiatry; 2012 Jul; 73(7):967-76. PubMed ID: 22687487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Concise Health Risk Tracking Self-Report (CHRT-SR) assessment of suicidality in depressed outpatients: A psychometric evaluation.
    De La Garza N; Rush AJ; Killian MO; Grannemann BD; Carmody TJ; Trivedi MH
    Depress Anxiety; 2019 Apr; 36(4):313-320. PubMed ID: 30370613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between irritability and suicidal ideation in three clinical trials of adults with major depressive disorder.
    Jha MK; Minhajuddin A; Chin Fatt C; Kircanski K; Stringaris A; Leibenluft E; Trivedi MH
    Neuropsychopharmacology; 2020 Dec; 45(13):2147-2154. PubMed ID: 32663842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report.
    Fava M; Rush AJ; Wisniewski SR; Nierenberg AA; Alpert JE; McGrath PJ; Thase ME; Warden D; Biggs M; Luther JF; Niederehe G; Ritz L; Trivedi MH
    Am J Psychiatry; 2006 Jul; 163(7):1161-72. PubMed ID: 16816220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychometric Properties of the Concise Associated Symptom Tracking Scale and Validation of Clinical Utility in the EMBARC Study.
    Minhajuddin A; Jha MK; Fatt CC; Trivedi MH
    Psychiatr Res Clin Pract; 2020; 2(1):10-18. PubMed ID: 36101888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do baseline sub-threshold hypomanic symptoms affect acute-phase antidepressant outcome in outpatients with major depressive disorder? Preliminary findings from the randomized CO-MED trial.
    Jha MK; Malchow AL; Grannemann BD; Rush AJ; Trivedi MH
    Neuropsychopharmacology; 2018 Oct; 43(11):2197-2203. PubMed ID: 30135556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Worsening Anxiety, Irritability, Insomnia, or Panic Predicts Poorer Antidepressant Treatment Outcomes: Clinical Utility and Validation of the Concise Associated Symptom Tracking (CAST) Scale.
    Jha MK; Minhajuddin A; South C; Rush AJ; Trivedi MH
    Int J Neuropsychopharmacol; 2018 Apr; 21(4):325-332. PubMed ID: 29182724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report.
    Bobo WV; Chen H; Trivedi MH; Stewart JW; Nierenberg AA; Fava M; Kurian BT; Warden D; Morris DW; Luther JF; Husain MM; Cook IA; Lesser IM; Kornstein SG; Wisniewski SR; Rush AJ; Shelton RC
    J Affect Disord; 2011 Oct; 133(3):467-76. PubMed ID: 21601287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Augmentation Strategies in Major Depression.
    Martiny K
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploratory analyses of effect modifiers in the antidepressant treatment of major depression: Individual-participant data meta-analysis of 2803 participants in seven placebo-controlled randomized trials.
    Noma H; Furukawa TA; Maruo K; Imai H; Shinohara K; Tanaka S; Ikeda K; Yamawaki S; Cipriani A
    J Affect Disord; 2019 May; 250():419-424. PubMed ID: 30878654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study.
    Rush AJ; Trivedi MH; Stewart JW; Nierenberg AA; Fava M; Kurian BT; Warden D; Morris DW; Luther JF; Husain MM; Cook IA; Shelton RC; Lesser IM; Kornstein SG; Wisniewski SR
    Am J Psychiatry; 2011 Jul; 168(7):689-701. PubMed ID: 21536692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trial of Psilocybin versus Escitalopram for Depression.
    Carhart-Harris R; Giribaldi B; Watts R; Baker-Jones M; Murphy-Beiner A; Murphy R; Martell J; Blemings A; Erritzoe D; Nutt DJ
    N Engl J Med; 2021 Apr; 384(15):1402-1411. PubMed ID: 33852780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What to Expect When Switching to a Second Antidepressant Medication Following an Ineffective Initial SSRI: A Report From the Randomized Clinical STAR*D Study.
    Rush AJ; South C; Jha MK; Jain SB; Trivedi MH
    J Clin Psychiatry; 2020 Aug; 81(5):. PubMed ID: 32780949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validating pre-treatment body mass index as moderator of antidepressant treatment outcomes: Findings from CO-MED trial.
    Jha MK; Wakhlu S; Dronamraju N; Minhajuddin A; Greer TL; Trivedi MH
    J Affect Disord; 2018 Jul; 234():34-37. PubMed ID: 29522941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.